MA40249A - Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation - Google Patents

Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation

Info

Publication number
MA40249A
MA40249A MA040249A MA40249A MA40249A MA 40249 A MA40249 A MA 40249A MA 040249 A MA040249 A MA 040249A MA 40249 A MA40249 A MA 40249A MA 40249 A MA40249 A MA 40249A
Authority
MA
Morocco
Prior art keywords
methods
aryle
manufacturing processes
receptor modulators
compounds
Prior art date
Application number
MA040249A
Other languages
English (en)
Inventor
Salvatore Bellinvia
Salvatore Demartis
Francesca Viti
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MA40249A publication Critical patent/MA40249A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne en général des composés qui peuvent se lier au récepteur d'hydrocarbure aryle et moduler son activité. Elle concerne des méthodes utilisant ces composés pour le traitement d'affections inflammatoires, telles que la maladie de crohn; et des compositions pharmaceutiques comprenant ces composés. L'invention concerne également des méthodes permettant d'augmenter les niveaux d'il-22 chez un sujet et/ou de réduire les taux d'ifn-
MA040249A 2014-06-27 2015-06-26 Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation MA40249A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017959P 2014-06-27 2014-06-27
US201462056054P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
MA40249A true MA40249A (fr) 2017-05-03

Family

ID=53491525

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040249A MA40249A (fr) 2014-06-27 2015-06-26 Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation

Country Status (15)

Country Link
US (4) US11427600B2 (fr)
EP (2) EP4406957B1 (fr)
JP (4) JP6616790B2 (fr)
KR (3) KR102505901B1 (fr)
CN (3) CN106536520B (fr)
AU (4) AU2015279047B2 (fr)
BR (1) BR112016030690B1 (fr)
CA (1) CA2952897A1 (fr)
DK (1) DK3160964T3 (fr)
ES (1) ES2978930T3 (fr)
FI (1) FI3160964T3 (fr)
MA (1) MA40249A (fr)
MX (3) MX388871B (fr)
PT (1) PT3160964T (fr)
WO (1) WO2015197861A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Il-22二聚体在制备静脉注射药物中的应用
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
WO2017181143A1 (fr) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Utilisation d'il-22 pour le traitement de l'entérocolite nécrosante
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
EP4219495A1 (fr) * 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Modulateurs de ahr
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
WO2020072675A1 (fr) * 2018-10-02 2020-04-09 Northwestern University Bêta-carbolines servant de modulateurs allostériques positifs du récepteur humain de la sérotonine 2c (5-ht2c)
EP3715471A1 (fr) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ensemble de marqueur de signature d'ahr
EP3721894A1 (fr) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gène 1 induit par l'interleukine-4 (il4i1) en tant que biomarqueur et ses utilisations
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
EP3835432A1 (fr) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gène 1 induit par l'interleukine-4 (il4i1) et métabolites respectifs en tant que biomarqueurs pour le cancer
EP4106794A4 (fr) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd Procédés de traitement d'une maladie du greffon contre l'hôte
MX2022012739A (es) * 2020-04-17 2022-11-07 Dong A St Co Ltd Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
EP4267578A4 (fr) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC Modulateurs du récepteur des éstrogènes
CN114456178B (zh) * 2021-01-13 2023-06-02 北京华森英诺生物科技有限公司 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
CN120965691B (zh) * 2025-10-20 2026-03-24 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) 一种2, 3, 4, 9-四氢-1H-吡啶[3,4-b]吲哚类化合物及制备方法和应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345376A (en) * 1963-11-06 1967-10-03 Upjohn Co Polyhydro-6-methoxy-1-(3, 4, 5-trimethoxyphenyl)-9h-pyrido[3, 4-b]indoles
JPH03287586A (ja) 1990-04-02 1991-12-18 Taisho Pharmaceut Co Ltd テトラヒドロ―β―カルボリン誘導体
KR20000005175A (ko) 1996-04-04 2000-01-25 프리돌린 클라우스너, 롤란드 비. 보레르 테트라하이드로-베타-카르볼린 유도체의 항전이제로서의 용도
ATE244717T1 (de) * 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
CA2285548C (fr) 1997-04-04 2006-07-11 Pfizer Products Inc. Derives de nicotinamide
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
US5939417A (en) * 1998-10-19 1999-08-17 Cell Pathways Inc 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia
AU7446600A (en) 1999-10-01 2001-05-10 Japan Energy Corporation Novel diarylamide derivatives and use thereof as medicines
US7091240B2 (en) * 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
GB0011098D0 (en) 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
GB0021831D0 (en) 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
US20020151534A1 (en) 2001-02-02 2002-10-17 Ries Uwe Joerg Antithrombotic compounds
MXPA03006648A (es) 2001-02-02 2003-10-15 Boehringer Ingelheim Pharma Compuestos antitombroticos, su preparacion y su utilizacion como medicamentos.
US6720331B2 (en) * 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
US7375131B2 (en) 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
US7138529B2 (en) 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
WO2004099170A2 (fr) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Acides carboxyliques substitues par phenyle
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7601840B2 (en) * 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
JP2008508356A (ja) 2004-08-02 2008-03-21 スミスクライン ビーチャム コーポレーション Hpv感染に有用な化合物
WO2006052722A1 (fr) 2004-11-09 2006-05-18 Smithkline Beecham Corporation Composes inhibiteurs de la phosphorylase du glycogene et compositions pharmaceutiques les comprenant
EP1817025A2 (fr) * 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles en tant qu'agents actifs permettant d'inhiber la production de vegf par regulation de la traduction
GB0503053D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
JP2008543915A (ja) 2005-06-21 2008-12-04 ノイロサーチ アクティーゼルスカブ 2−(フェニルアミノ)ベンズイミダゾール誘導体及び低コンダクタンスカルシウム依存性カリウムチャネルのモジュレーターとしてのそれらの使用
EP1764096A1 (fr) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Nouveaux derivés de phloroglucinol ayant activité de ligande de selectine
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
US20090012075A1 (en) 2006-01-12 2009-01-08 Miller Thomas A Fluorinated Arylamide Derivatives
CA2639913A1 (fr) 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Composes a base de phenyle et de pyridyle pour des utilisations liees aux inflammations ou aux troubles immunitaires
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
CA2648804C (fr) 2006-04-07 2014-05-27 Methylgene Inc. Derives de benzamide utilises en tant qu'inhibiteurs de l'histone desacetylase
EP2032562B1 (fr) 2006-05-12 2010-08-25 Vertex Pharmaceuticals Incorporated Inhibiteurs sélectifs de protéine kinase rock et utilisations de ceux-ci
KR20090024823A (ko) 2006-06-30 2009-03-09 세프라코 아이엔시. D-아미노산 옥시다제의 융합된 헤테로사이클 억제제
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US8440711B2 (en) 2006-12-19 2013-05-14 Dompe Pha.R.Ma S.P.A. 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them
JP2010120852A (ja) 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd 新規なジアミド誘導体
AU2008225922B2 (en) * 2007-03-15 2012-04-26 F. Hoffmann-La Roche Ag Malonamides as orexin antagonists
US20100158858A1 (en) * 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2009042294A2 (fr) 2007-08-10 2009-04-02 Burnham Institute For Medical Research Activateurs de la phosphatase alcaline non spécifique des tissus (tnap) et leurs utilisations
WO2009073620A2 (fr) 2007-11-30 2009-06-11 Newlink Genetics Inhibiteurs de l'ido
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2734500A1 (fr) 2008-08-27 2010-03-11 Calcimedica Inc. Composes qui modulent le calcium intracellulaire
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
WO2010148350A1 (fr) * 2009-06-18 2010-12-23 Cornell University Photoproduits du tryptophane, leur synthèse et leurs utilisations
AR077823A1 (es) * 2009-08-11 2011-09-28 Sanofi Aventis Us Llc Proceso para preparar compuestos de benzimidazol sustituidos con 2-arilamino o heteroarilamino
WO2011058139A1 (fr) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. Composé, procédé pour sa préparation, composition pharmaceutique, utilisation d'un composé, procédé de modulation ou de régulation de serine/thréonine kinases et agent modulateur de sérine/thréonine kinases
US8509802B2 (en) * 2010-05-26 2013-08-13 Qualcomm Incorporated Methods and apparatus supporting load balancing in a wireless communications system
US20130171103A1 (en) 2010-05-27 2013-07-04 Ptc Therapeutics, Inc. Methods for treating viral conditions
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
JP6215924B2 (ja) 2012-06-19 2017-10-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規の二環式チオフェニルアミド化合物
AR091654A1 (es) 2012-07-02 2015-02-18 Biogen Idec Inc COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g
WO2014055644A2 (fr) 2012-10-02 2014-04-10 New York University Compositions pharmaceutique et traitement de maladies génétiques associées à une désintégration d'arn à médiation non-sens
EP2738173A1 (fr) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Composés hétérocycliques comme inhibiteurs du symporteur d'iodure de sodium
CN103864779B (zh) 2012-12-07 2016-06-22 天津科技大学 一种1-(苯基)-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚衍生物的制备及其在抗肿瘤药物中的应用
KR101453413B1 (ko) 2013-01-29 2014-11-12 순천향대학교 산학협력단 알파-카르볼린 유도체의 제조방법
US20160030389A1 (en) 2013-03-13 2016-02-04 Alevere Medical Corporation Use of indole compounds for fat reduction and skin and soft tissue tightening
PL2989106T3 (pl) 2013-04-25 2017-08-31 Beigene, Ltd. Połączone związki heterocykliczne jako inhibitory kinazy białkowej
CA3122383A1 (fr) 2013-05-07 2014-11-13 Galapagos Nv Nouveaux composes et leurs compositions pharmaceutiques pour le traitement de la mucoviscidose.
WO2015162216A1 (fr) 2014-04-24 2015-10-29 Universita' Degli Studi Di Siena Dérivés de biaryl amide ou d'urée en tant que ligands de trpv1
JP6545197B2 (ja) 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびmalt1阻害剤としてのその使用
US11427600B2 (en) 2014-06-27 2022-08-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
JP2019001715A (ja) 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
MX2019000864A (es) 2016-07-20 2019-06-03 Univ Columbia Activadores de histona acetiltransferasa y sus composiciones y usos.
EP3558992A4 (fr) 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. Activateur de canaux trek (canaux k+ associés à twik)
CN107880040A (zh) 2017-12-22 2018-04-06 中国药科大学 一种四氢β-咔啉类衍生物及其制备方法与用途

Also Published As

Publication number Publication date
WO2015197861A1 (fr) 2015-12-30
MX2017000135A (es) 2017-04-10
KR102747416B1 (ko) 2024-12-27
EP4406957B1 (fr) 2026-04-08
PT3160964T (pt) 2024-06-07
ES2978930T3 (es) 2024-09-23
KR20230035446A (ko) 2023-03-13
JP2021185192A (ja) 2021-12-09
FI3160964T3 (fi) 2024-06-11
NZ727475A (en) 2023-10-27
JP2023184714A (ja) 2023-12-28
MX2021015632A (es) 2022-02-03
EP4406957A3 (fr) 2024-10-16
US20250066384A1 (en) 2025-02-27
CN106536520B (zh) 2020-08-14
CN111978319B (zh) 2023-08-11
AU2019280023A1 (en) 2020-01-16
CN116947880A (zh) 2023-10-27
KR20170020517A (ko) 2017-02-22
AU2021250993A1 (en) 2021-11-11
EP3160964A1 (fr) 2017-05-03
JP6941147B2 (ja) 2021-09-29
JP2020019823A (ja) 2020-02-06
KR20250004174A (ko) 2025-01-07
CN106536520A (zh) 2017-03-22
AU2015279047B2 (en) 2020-01-02
US20170158707A1 (en) 2017-06-08
KR102505901B1 (ko) 2023-03-08
MX388871B (es) 2025-03-20
CA2952897A1 (fr) 2015-12-30
AU2015279047A1 (en) 2017-01-12
JP6616790B2 (ja) 2019-12-04
US11427600B2 (en) 2022-08-30
DK3160964T3 (da) 2024-06-03
US20230234963A1 (en) 2023-07-27
CN111978319A (zh) 2020-11-24
US12577256B2 (en) 2026-03-17
AU2024203413A1 (en) 2024-06-13
BR112016030690A2 (pt) 2017-10-31
BR112016030690B1 (pt) 2023-11-14
AU2019280023B2 (en) 2021-07-29
JP7432562B2 (ja) 2024-02-16
EP3160964B1 (fr) 2024-03-13
US12012418B2 (en) 2024-06-18
CN116947880B (zh) 2025-11-21
EP4406957A2 (fr) 2024-07-31
AU2021250993B2 (en) 2024-02-22
US20260176287A1 (en) 2026-06-25
JP2017520561A (ja) 2017-07-27
MX2021015631A (es) 2022-02-03

Similar Documents

Publication Publication Date Title
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP2916860A4 (fr) Composition pour le traitement du diabète ou de la diabésité comprenant un analogue d'oxyntomoduline
MA38261A1 (fr) Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc)
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
UA122528C2 (uk) Сполуки, які модулюють fxr (nr1h4)
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
JOP20200157A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
EA201792047A1 (ru) Новые соединения
MX395317B (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
MA38814B2 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
MA47442A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
MA39342A1 (fr) Anticorps il -21
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EP4406957A3 (fr) Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation
EA201171063A1 (ru) Фармацевтические составы олмесартана